Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors-Reference-Cited by-同舟云学术

Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors

Published:2022-07 Issue:7 Volume:40 Page:346.e1-346.e8
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Fukuokaya Wataru^ORCID,Kimura Takahiro^ORCID,Komura Kazumasa,Uchimoto Taizo,Nishimura Kazuki,Yanagisawa Takafumi,Imai Yu,Iwatani Kosuke,Ito Kagenori,Urabe Fumihiko,Tsuzuki Shunsuke,Kimura Shoji,Terada Naoki,Mukai Shoichiro,Oyama Yu,Abe Hirokazu,Kamoto Toshiyuki,Azuma Haruhito,Miki Jun,Egawa Shin

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference29 articles.

1. Long-Term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005

2. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017

3. Management of urothelial bladder cancer in clinical practice: Real-world answers to difficult questions;Mar;J Oncol Pract,2019

4. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non–small cell lung cancer;Zhao;Lung Cancer,2019

5. Efficacy of chemotherapy and atezolizumab in patients with non–small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials;Chalabi;Annals Oncol,2020

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration;Cancer Treatment Reviews;2024-09

2. Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab;Clinical Genitourinary Cancer;2024-08

3. Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab;International Journal of Clinical Oncology;2024-03-02

4. Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis;Journal for ImmunoTherapy of Cancer;2024-03

5. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18